To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
The goals of the Population Studies and Disparities Research (PSDR) Program include identifying risk factors underlying disease onset and progression, and developing and testing intervention strategies to reduce risk and improve diagnosis, treatment and outcomes. These goals are aimed at decreasing race and ethnicity related disparities and overall disease burden.
The PSDR Program themes encompass research to reduce and eliminate disparities across the cancer experience of adult and pediatric populations, and include a diversity of race/ethnic groups.
Members of the Population Studies & Disparities Research Program regularly interact in several ways to develop scientific directions and implement strategic planning efforts including:
The metropolitan Detroit area is home to a highly diverse and medically underserved population. As part of the original SEER program of nine registries dating back to 1973, we contribute approximately 38% of the national cancer incidence and survival data for African Americans. The SEER registry is not only used for descriptive studies; it provides a population-based source of cases for case-control and case-case comparisons. There are ~25,000 new cancers diagnosed in Metropolitan Detroit each year, with about 25% of those being diagnosed in African Americans. In addition to the large African American population, this area is home to the largest concentration of Arab Americans in the United States. This population diversity provides a remarkable opportunity for the study of race/ethnicity related health disparities. All of the research described is conducted in this context and includes substantial numbers of minorities.
Program Leader, Population Studies and Disparities Research Program Associate Professor, Department of Oncology Director, Epidemiology Research Core Karmanos Cancer Institute Wayne State University School of Medicine
Co-Program Leader, Population Studies and Disparities Research Associate Professor, Department of Oncology Karmanos Cancer Institute Wayne State University School of Medicine
A recent study published in Scientific Reports correlates higher levels of pollutant particulate matter to higher occurrences of head and neck aer...
GQ Anthony Shields, M.D., Ph.D. , medical oncologist and member of the Gastrointestinal and Neuroendocrine Oncology and the Phas...
Mary Lou Brose never imagined having a CT scan of her back could be life-changing, but results from the test turned her world upside down. A...